-
Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Rochester, MN
The purpose of this study is to evaluate the effectiveness of a 24-dose course of weekly treatment with a T-cell co-stimulation inhibitor (abatacept (Orencia)) plus usual care versus usual care subjects from the CARRA Registry to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication (s) for JIA (i.e. one or more of the following: systemic glucocorticoids, DMARD or biologic) medication within 12 months of enrollment in children with recent-onset limited JIA
-
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
Rochester, MN
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
-
A Study of Whole Blood-based Blood Biomarker (i.e., cytokine) that May Predict Status and Severity of Diseases
Rochester, MN
The purpose of this study is to see if whole blood-based blood biomarker (i.e., cytokine) predicts status and severity of diseases such as asthma, Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis (RA), or Inflammatory Bowel Disease (IBD).